Induction Chemotherapy With an Anti-GD2 Monoclonal Antibody (Dinutuximab) and Cytokines in Children With Newly Diagnosed High-risk Neuroblastoma: A Case Series
- Resource Type
- Authors
- Wayne L. Furman; Sara M. Federico; Jessica Gartrell; Kenneth J. Caldwell; Sara Helmig; Barry L. Shulkin
- Source
- Journal of Pediatric Hematology/Oncology. 43:e692-e696
- Subject
- Male
Oncology
medicine.medical_specialty
medicine.drug_class
medicine.medical_treatment
Antineoplastic Agents
Disease
Monoclonal antibody
Neuroblastoma
03 medical and health sciences
0302 clinical medicine
Internal medicine
Humans
Medicine
Retrospective Studies
Chemotherapy
business.industry
Antibodies, Monoclonal
Infant
Dinutuximab
Induction chemotherapy
Induction Chemotherapy
Hematology
medicine.disease
Minimal residual disease
Regimen
Child, Preschool
030220 oncology & carcinogenesis
Pediatrics, Perinatology and Child Health
Cytokines
Female
business
030215 immunology
- Language
- ISSN
- 1077-4114
Although outcomes for patients with high-risk neuroblastoma improved after the addition of a chimeric anti-GD2 monoclonal antibody (dinutuximab) as treatment for minimal residual disease, nearly half of these patients die of disease. Recent studies demonstrated efficacy of the combination of chemotherapy with anti-GD2 mAb in patients with relapsed or newly diagnosed disease. This retrospective case series describes 6 patients treated at St Jude Children's Research Hospital with an induction regimen containing dinutuximab and chemotherapy, followed by consolidation and postconsolidation therapy. The treatment was well tolerated with expected toxicities. All patients completed induction therapy and demonstrated a clinical response. Further studies are warranted.